Systemic Lupus Erythematosus (SLE) Prospective Observational CohortStudy (SPOCS)

The purpose of this study is to methodically describe the patient experience of living with SLE, by studying the clinical features of the disease, how the disease progresses, how it is treated and how it affects quality of life. The study aims to look at the treatment outcomes and assess how patients with moderate to severe SLE utilize the available health resources. This study will also increase understanding of the type 1 interferon gene signature in SLE. A gene signature is a group of genes in a cell who may have an effect on cells, tissues or the medical condition. Therefore this study explores how the gene signature of type 1 interferon protein may be linked with how SLE starts and develops over time.

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

*Adult patients aged 18 years of age or older
*Diagnosed with moderate-to-severe SLE
*Treated for a minimum of 6 months with SLE treatment, excluding topical treatment, beyond nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics (painkillers)
*Patients actively enrolled in interventional trials involving investigational agents are not eligible.
*Patients with active severe lupus nephritis with a history of a renal biopsy in the last year are not eligible.

Primary disease category: Arthritis

Sponsor: AstraZeneca

Projected enrollment dates: August 2017 to August 2022

Official study title: Systemic Lupus Erythematosus (SLE) Prospective Observational CohortStudy (SPOCS)